ABSTRACT Background Continued SARS-CoV-2 infections and COVID-19-related
hospitalizations highlight the need for effective anti-viral treatments in the outpatient setting …

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; …

Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind …

Background The monoclonal antibody combination casirivimab and imdevimab (REGEN-
COV®) reduced viral load, hospitalisation, or death when administered 1: 1 as an …

Background In vitro studies suggesting that REGEN-COV (casirivimab plus imdevimab
monoclonal antibodies) had poor efficacy against Omicron-variant SARS-CoV-2 infection …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Objective: Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab
antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS …

Background REGEN-COV (previously known as REGN-COV2), a combination of the
monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the …

Abstract Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …